Navigation Links
Congresso ESH 2013, dallo studio SEVITENSION nuove evidenze sull'efficacia della combinazione fissa olmesartan/amlodipina vs. perindopril/amlodipina nel controllo della pressione arteriosa centrale
Date:6/25/2013

MILANO, June 25, 2013 /PRNewswire/ --

Nel corso del 23° Congresso della Società Europea di Ipertensione sono stati presentati gli ultimi dati dello studio SEVITENSION, che mostrano l'efficacia superiore della combinazione fissa olmesartan/amlodipina rispetto alla combinazione perindopril/amlodipina nel controllo della pressione arteriosa centrale. SEVITENSION prende le mosse dai risultati del precedente studio CAFÉ-Conduit Artery Function Evaluation (parte dello studio ASCOT), che aveva mostrato come i trattamenti in combinazione fissa abbiano effetti differenti sulla pressione arteriosa centrale.

"Queste evidenze - ha dichiarato Luis Ruilope, direttore dell'Unità Antipertensiva dell'Ospedale 12 Ottobre di Madrid e coordinatore dello studio Sevitension - potrebbero spiegare la differenza dei risultati clinici fra i due gruppi dello studio ASCOT e fornire utili indicazioni per aiutare i medici a scegliere la miglior opzione di trattamento per gestire in maniera più efficace e conveniente l'ipertensione, proteggendo i pazienti dal rischio cardiovascolare. L'ambizione è quella di raggiungere l'obiettivo di controllare adeguatamente la pressione arteriosa nel 70% dei pazienti entro il 2015".

Gli inibitori dell'enzima di conversione dell'angiotensina (ACE-I) agiscono bloccando l'enzima che trasforma l'angiotensina I in angiotensina II, mentre gli ARB agiscono bloccando il recettore dell'angiotensina II, offrendo peraltro il vantaggio di minori effetti collaterali rispetto agli ACE-I, in particolare la tosse.

Daiichi Sankyo continua il proprio impegno nell'ipertensione e nello sviluppo dell'olmesartan. Lo studio SEVITENSION si è concentrato proprio sulla valutazione della combinazione fissa olmesartan/amlodipina.

Lo studio SEVITENSION ha analizzato la combinazione di 40 mg di
'/>"/>

SOURCE Daiichi Sankyo Europe GmbH
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. New Online Course Helps Employers Comply with OSHA’s Dec. 1, 2013, GHS Training Deadline
2. MedZilla.com Launches New Site Design for 2013, Slick New Interface Impresses
3. VIASPACE Chairman and CEO Attend EUEC 2013, Giant King Grass Prominently Featured in Convention Exhibit Hall
4. Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2012 On Thursday, February 28, 2013, After Close of U.S.-Based Financial Markets
5. Retraction of Press Release Dated March 7, 2013, Regarding Recipient of Alumni Award from Johns Hopkins University
6. CANVUS Design Studio Specializes in Graphic Design and Commercials
7. Accelrys Materials Studio Release 6.1 Speeds Innovation with Enterprise Capabilities
8. Temple Run Gamers Have a New IOS Game To Play, Dream Bot Studios Explains
9. Elsevier Launches Web-Based Pathway Studio and Adds New Molecular Data from Its Biology Journals to Boost Early Discovery Research
10. Winding River Productions Announces High-End Studio Enhancements Including SCORM-Compliant e-Learning Media Development and On-Location Data and Media Capture Platforms
11. Il Ministero della sanità canadese ha concesso le indicazioni sulla salute rivendicate da cinque formulazioni probiotiche di Lallemand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... A new report, commissioned by BioCrossroads and conducted by ... at Indiana,s capital market and ... time frames: 1993 to 2002 and 2003 to 2013.  ... investment growth.  The Life Science Innovation Capital in ... innovation dollars as well as an increase in life ...
(Date:10/30/2014)... of the key challenges in the development of quantum ... , In a paper published today (28 October) in ... show how to make a new type of flexibly ... such as high-precision sensors and specialised superfast computers, often ... the methods for trapping these tiny particles are hugely ...
(Date:10/27/2014)... October 27, 2014 Ryan Carfley , ... month to sit down with Bryan Hamilton, the publisher of ... to discuss talent in the Research Triangle region of North ... were highlighted at the roundtable include the role of ... significance of work/life balance and the unique role that Millennials ...
(Date:10/27/2014)... -- The Italian company Roadrunnerfoot has ... its artificial "lower limb", after the German giant ...      (Photo: http://photos.prnewswire.com/prnh/20141027/713097 ) , ... judgement has arrived: Roadrunnerfoot, the small Italian company ... prostheses with composite materials, has won against global ...
Breaking Biology Technology:New report shows Indiana's gains in life sciences innovation capital outpace the nation 2New report shows Indiana's gains in life sciences innovation capital outpace the nation 3New report shows Indiana's gains in life sciences innovation capital outpace the nation 4New report shows Indiana's gains in life sciences innovation capital outpace the nation 5Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2
... - Transaction Includes $10 Million in Upfront Fees ... ACCESS PHARMACEUTICALS, INC.,(OTC Bulletin Board: ACCP) and Milestone ... definitive license agreement under which,Milestone will market Access, ... Milestone is a company recently started by former,executives ...
... Radiopharmaceutical production facility to support clinical development for ... lead drug candidate and ... Inc., a,privately-held radiopharmaceutical company that designs, develops and,manufactures products ... it has completed commissioning its in-house manufacturing,capability to meet ...
... /Xinhua-PRNewswire-FirstCall/ -- Lotus,Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or ... today announced financial results for the quarter and six months,ended ... -- Total revenues increased to $19.4 million, up 51.4% from ... -- Gross profit was $9.7 million, up 76.4% from the ...
Cached Biology Technology:Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America 2Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America 3Cellectar, Inc. Begins GMP Production 2Lotus Pharmaceuticals Announces Second Quarter 2008 Results 2Lotus Pharmaceuticals Announces Second Quarter 2008 Results 3Lotus Pharmaceuticals Announces Second Quarter 2008 Results 4Lotus Pharmaceuticals Announces Second Quarter 2008 Results 5Lotus Pharmaceuticals Announces Second Quarter 2008 Results 6Lotus Pharmaceuticals Announces Second Quarter 2008 Results 7Lotus Pharmaceuticals Announces Second Quarter 2008 Results 8Lotus Pharmaceuticals Announces Second Quarter 2008 Results 9Lotus Pharmaceuticals Announces Second Quarter 2008 Results 10Lotus Pharmaceuticals Announces Second Quarter 2008 Results 11Lotus Pharmaceuticals Announces Second Quarter 2008 Results 12Lotus Pharmaceuticals Announces Second Quarter 2008 Results 13Lotus Pharmaceuticals Announces Second Quarter 2008 Results 14Lotus Pharmaceuticals Announces Second Quarter 2008 Results 15
(Date:10/30/2014)... Oct. 29, 2014  Securus Technologies, a ... technology solutions for public safety, investigation, corrections ... deployed exciting enhancements to its THREADS™ product, ... provide actionable intelligence and focused leads for ... drive technological innovation through identifying and delivering ...
(Date:10/29/2014)... kind to date, researchers have used DNA sequencing to ... autism. Joseph Buxbaum, Ph.D., Icahn School of Medicine at ... Institute of Harvard and MIT, and their colleagues examined ... and unrelated people. They identified changes in 107 genes ... autism spectrum disorder (ASD) – a jump from the ...
(Date:10/29/2014)... and environmental, have been blamed for increasing the ... as a family history of schizophrenia, are widely ... gondii , a parasite transmitted by soil, undercooked ... skepticism. , A new study by Gary Smith, ... University of Pennsylvania,s School of Veterinary Medicine, used ...
Breaking Biology News(10 mins):Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2Penn vet professor investigates parasite-schizophrenia connection 2Penn vet professor investigates parasite-schizophrenia connection 3
... Access to Research Careers) Program has announced the travel ... of Chicanos and Native Americans in Science (SACNAS) annual ... These awards are meant to promote the entry of ... mainstream of the basic science community and to encourage ...
... Fox Foundation for Parkinson,s Research and Shake It Up ... Sydney,s Garvan Institute of Medical Research to look at ... Long non-coding RNAs are complex molecules, produced from ... in the body. Unlike conventional genes, they do not ...
... have increasingly relied on the wild and weedy relatives of ... and other traits. But just like all wild plant species, ... decline and extinction due to habitat loss, pollution, and climate ... describe the latest efforts to identify and protect the wild ...
Cached Biology News:Garvan Institute receives grant to research role of long non-coding RNAs in Parkinson's disease 2Protecting the weedy and wild kin of globally important crops 2
Troponin I Immunogen: Full length native protein (purified) (Human). Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
Microlite 1+ 1x12 Strip assembled, flat bottom; the ideal vessel for low signal luminescent reactions, offering medium binding with enhanced dynamic range, extra high reflectivity and minimal cross t...
... pressurized syringe holder for any researcher who needs: ... Microinjecting Fine microliter delivery Small ... any new or existing perfusion rig - from ... to house air or a compressor (30 to ...
Biology Products: